In addition, targeting ERK1 and ERK2 by inhibiting the expression of GRB2, which is a potent activator of ERK1 and ERK2, has been shown to be effective in the treatment of CML patients with refractory or relapsed disease34,35. Here, MAPK3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.